TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00943917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ITCA 650
Description: ITCA 650 (continuous delivery of exenatide in DUROS)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ITCA 650
Description: ITCA 650 (continuous delivery of exenatide in DUROS)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ITCA 650
Description: ITCA 650 (continuous delivery of exenatide in DUROS)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ITCA 650
Description: ITCA 650 (continuous delivery of exenatide in DUROS)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ITCA 650
Description: ITCA 650 (continuous delivery of exenatide in DUROS)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ITCA 650
Description: ITCA 650 (continuous delivery of exenatide in DUROS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide Injection
Description: twice daily (BID) injections of exenatide commercially available Byetta: 5 mcg/dose first 12 weeks then 10 mcg/dose for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ex Inj/ITCA 650
Description: twice-daily (BID) exenatide injection: 5 mcg/dose for 4 weeks then 10 mcg/dose for 8 weeks, followed by ITCA 650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ex Inj/ITCA 650
Description: twice-daily (BID) exenatide injection: 5 mcg/dose for 4 weeks then 10 mcg/dose for 8 weeks, followed by ITCA 650
Study: NCT03095872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2-laser
Description: Patients with photo-damaged skin are treated with the CO2 laser to remove damaged skin layers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaseline
Description: After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Vaseline, and be marked V. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Vaseline. In the next seven days the patient will repeat the treatment every day at home.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepanthen
Description: After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Bepanthen® Wund- und Heilsalbe, and be marked B. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Bepanthen® Wund- und Heilsalbe. In the next seven days the patient will repeat the treatment every day at home.
Study: NCT03631407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicriviroc
Description: Vicriviroc tablets administered orally, QD at dose level 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicriviroc
Description: Vicriviroc tablets administered orally, QD at dose level 1 or 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered by IV infusion at 200 mg every 3 weeks (Q3W), given on cycle day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered by IV infusion at 200 mg every 3 weeks (Q3W), given on cycle day 1.
Study: NCT03447457

Intervention type: DEVICE
Group type: OTHER
Intervention: High-flow oxygen
Description: HFNC is continuously applied via large-bore nasal prongs with a gas flow rate of 50 L/min and a FiO2 adjusted to maintain a pulse oxymetry at least 92%

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard oxygen
Description: nasal cannula, face mask or non-rebreathing reservoir mask
Study: NCT02357472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dehydroepiandrosterone
Description: high dose group treatment represent for 50mg t.i.d and standard dose group represents for normal treatment with 25mg t.i.d. Each patients in these two group will take one capsule each time and three times a day for three months before entering into IVF cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dehydroepiandrosterone
Description: high dose group treatment represent for 50mg t.i.d and standard dose group represents for normal treatment with 25mg t.i.d. Each patients in these two group will take one capsule each time and three times a day for three months before entering into IVF cycles.
Study: NCT01160354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Starting at 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before a 1 hour (+/- 30 minutes) IV administration of Clofarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Fixed dose of 30 mg/m2/day during Induction cycle (20 mg/m2/day in consolidation cycles).
Study: NCT02426229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: dabigatran etexilate 75mg orally twice a day for 6 months
Study: NCT03247842

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suprascapular nerve block
Description: Sixty patients with shoulder dystocia after breast surgery will receive stellate ganglion neurolysis with supra-scapular nerve radiofrequency,

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suprascapular nerve block
Description: Sixty patients with shoulder dystocia after breast surgery will receive stellate ganglion neurolysis with supra-scapular nerve radiofrequency,
Study: NCT04547764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triple antibiotic paste (TAP)
Description: root canal treatment of pulpally involved teeth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitapex (calcium hydroxide/iodoform paste)
Description: root canal treatment of pulpally involved teeth.
Study: NCT02463214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Engineered Room
Description: Touchless devices:~Hand sanitizers, faucets, paper towel dispensers, call devices, Ultraviolet C Aseptix™ Disinfection devices above bathroom doors~Copper products:~Room and bathroom entrance door hardware, over bed table and bed side table surfaces, chair metal arms, wardrobe handles and knobs, weigh scale, sinks, grab bars, light switch panels, toilet flush handles, faucets and handles, patient bed rails.~Titanium dioxide paint:~Room walls, head walls, light switches, bathroom wall shelves, toilet tank and bowl, head wall unit fixed equipment, television remote and Bed Control remote
Study: NCT04544319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zemiglo 50mg and Forxiga 10mg
Description: Each component of Gemigliptin 50mg QD and Dapagliflozin 10mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zemiglo 50mg and Forxiga 10mg
Description: Each component of Gemigliptin 50mg QD and Dapagliflozin 10mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg
Description: Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg
Description: Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg QD
Study: NCT02620306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimsartan 60mg~120mg
Description: Standard BP control group (SBP \< 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimsartan 60mg~120mg
Description: Strict BP control group (SBP \< 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 50mg~100mg
Description: Standard BP control group (SBP \< 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 50mg~100mg
Description: Strict BP control group (SBP \< 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
Study: NCT01145729

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biomarker Feedback
Description: Providing providers biomarker feedback on childhood secondhand smoke exposure

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Biomarker Feedback
Description: Providing providers biomarker feedback on childhood secondhand smoke exposure
Study: NCT03794024

Intervention type: DEVICE
Intervention: The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator
Description: The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.

Intervention type: DEVICE
Intervention: The Axium Neurostimulator System
Description: The Axium Neurostimulator System is indicated for spinal column stimulation via epidural and intra-spinal lead access to the dorsal root ganglion as an aid in the management of moderate to severe chronic intractable pain of the lower limbs in adult patients with Complex Regional Pain Syndrome Types I and II
Study: NCT00003222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Systemic subcutaneous delivery of low-dose IL-2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Systemic subcutaneous delivery of low-dose IL-2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus peptide melanoma vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus peptide melanoma vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tyrosinase peptide
Study: NCT04359511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: hémisuccinate d'hydrocortisone 3,5 mg/kg/jour (IV)
Study: NCT02929186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-In Outreach
Description: Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to elect to receive a home FIT kit or report prior screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-Out Outreach
Description: Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to choose not to receive a home FIT kit or report prior screening. A FIT kit will otherwise be sent to the subject as a default.
Study: NCT04122066

Intervention type: DRUG
Intervention: sofosbuvir \daclatsvir
Description: study the effect of the new oral antihepatitis C drugs on the respiratory system
Study: NCT04327739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 1 Exercise
Description: • Exercise programme Endurance and Resistant training exercise program (Duration: 45 minutes) • Muscle retraining of longus colli and endurance training of the deep cervical flexors. • Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM). • Active ROM exercises for the neck muscles • Upper limbs exercises with resistant bands • Stretching exercises for the neck and upper limbs muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 2 Exercise and INIT
Description: * Exercise programme same as Intervention Group 1 and~* Integrated Neuromuscular Inhibition Technique application. Integrated Neuromuscular Inhibition Technique application. (Duration: 15min) The protocol was applied to the following muscles: • Upper border of the trapezius muscle • sternocleidomastoid • levator scapulae muscle • splenius capitis muscle Integrated Neuromuscular Inhibition Technique includes the combination of the following technique: • Ischemic compression • Muscle energy technique • Straincounterstrain technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 3 Exercise and SMT
Description: * Exercise programme same as Intervention Group 1 and~* Manipulation Care. Participants allocated to this group received Spinal Manipulation Therapy after the therapeutic exercise programme. Treatment was delivered by 1 chiropractor with a minimum 5-year experience of clinical practice. Pain provocation and static/motion palpation findings were used to determine areas of treatment in the cervical spine. The Manipulation Therapy technique included joint motion using a diversified thrust technique, and mobilization, a low-velocity type of joint oscillation. The type and the force of the applied spinal manipulation were individualized according to the age and physical condition of each participant. Soft passive stretching, light massage and hot packs were applied to the cervical and upper thoracic area before manipulation in order to prepare each participant.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants allocated to this group received general consulting istructions and a home based general exercise sheet
Study: NCT03898089

Intervention type: OTHER
Group type: OTHER
Intervention: Core Stability Exercise
Description: The participants in the core stability exercise group will be included in a treatment program for 3 days per week for 6 weeks. Traditional physiotherapy methods will be applied to all participants. Traditional physiotherapy will include heat modality (a hot pack for 15 minutes), electrotherapy (transcutaneous electrical nerve stimulation (TENS), a 50 Hz conventional TENS with a pulse duration \<150 microseconds).Each training session will be lasted 60 min, starting with a 10-min warm up program mainly consisting of core strength exercises and ending with a 5-min cool-down program (stretching). Progression of exercises will be tailored to individual patients' ability, fatigue and pain. Exercises will be designed from 1 set to 3 sets, from 8 to 15 repetitions and contractions from 5 seconds to 10 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stability Exercise plus Myofascial Release Technique Group
Description: In addition to the core stabilization exercise group myofascial relaxation technique will be performed with roller massager (Theraband®, The Hygenic Corporation, Akron, OH.) for 3 days per week for 6 weeks. The myofascial relaxation technique will be performed along the superficial back line (plantar fascia gastrocnemius muscles, hamstring muscles, sacrolumbar fascia, erector spinae muscles) bilaterally. Myofascial relaxation will be done to the anatomical structures indicated by roller massage technique. Applications will be made in 3 sets of 30sec for each zone (1 min rest between sets) and 7/10 according to VAS.
Study: NCT02865421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stem cells
Description: adipose tissue derived stromal vascular fraction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: platelet rich plasma transplanted in bald area at a distance
Study: NCT01085734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: 1.25mg intravitreally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osurdex
Description: 0.7mg intravitreally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: 1.25mg intravitreally
Study: NCT03201432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting stent (DES)
Description: Polymer-free paclitaxel eluting stents

Intervention type: DEVICE
Group type: OTHER
Intervention: Bare metal stent (BES)
Description: Bare metal stent
Study: NCT01229709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Tinnitus Reduction
Description: The Mindfulness Based Tinnitus Reduction (MBTR) program will be held for two-and-a-half hours one evening per week over 8 consecutive weeks. Participants will also complete a day-long Sunday retreat between the 6th and 7th sessions. Each participant will take part in a 30-minute private interview with the course instructor prior to beginning the program.
Study: NCT04810949

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamine D3 supplementation
Description: 1. The supplementation treatment will consist of prescribing vitamin D3 consumption of 4000 U 13 single dose tablets each month (52,000 IU).
Study: NCT02378233

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iodine
Description: The intervention is to give a multivitamin pill including 150 microgram iodine and compare with a multivitamin pill that is not including iodine.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients are given a non-iodine containing multivitamin tablet
Study: NCT02467127

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D supplementation
Description: In patients with headache and with low vitamin D plasma levels, will be administered a vitamin D supplementation.
Study: NCT00003222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tyrosinase peptide
Study: NCT02467127

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D supplementation
Description: In patients with headache and with low vitamin D plasma levels, will be administered a vitamin D supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D supplementation
Description: In patients with headache and with low vitamin D plasma levels, will be administered a vitamin D supplementation.
Study: NCT03107052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab
Study: NCT02263326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir
Description: 50 mg tablet by mouth once daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamivudine
Description: 300 mg tablet by mouth once daily for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continue current antiretroviral regimen
Description: Continue current DHHS recommended or alternative three-drug antiretroviral regimen
Study: NCT04994028

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Behavioral and life style modification and dyspnea prevention education i.e. Sitting: Sit upright with back against chair, feet wide apart, leaning forward with arms on bedside table or on knees. Standing: Lean back against wall with feet slightly apart with head and shoulder relaxed. In Bed: Elevate head of the bed, support and elevate arms with pillow. Stairs: Lean forward with on banister when climbing stairs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment with volume Spirometry and deep breathing
Description: Group B or interventional group was received conventional treatment along with volume Spirometry and deep breathing exercise, total 5 breaths with 3sec inhalational breath hold for each breath at one session per day for volume Spirometry and for deep breathing exercise 10 times with breath hold 2sec at every session for 5 minutes 3 times per week for total duration of two weeks.
Study: NCT00841776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duac
Description: Clindamycon and benzoyl peroxide topical gel once a day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziana gel
Description: Clindamycin and tretinoin gel once a day for 12 weeks.
Study: NCT00141648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.
Description: Given intravenously on days 1,11,43: Cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2. Given orally on days 1-5,22-27: Pednisolone 50mg/m2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Total 45 Gy in 25 fractions
Study: NCT04982341

Intervention type: PROCEDURE
Intervention: prone position
Description: patients are returned from prone to supine position while receiving oxygenation through HFNC
Study: NCT02013778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ
Study: NCT00933608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine
Description: participants will be asked to take memantine (20mg/day) for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participants will be asked to take 2 tablets per day to match active drug
Study: NCT01388049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrosensing antibody probing system (e- Ab sensor)
Description: Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-EV71 antibody and its antigen (EV71) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (EV71) in the test specimens. From assessment of the electric signature of semiconductive anti-EV71 antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
Study: NCT00769171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Moxifloxacin 400 mg every 24 h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone + Metronidazole
Description: Ceftriaxone 2 g every 24 h and Metronidazole 500 mg every 12 h